Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: A prospective study

Mariantonia Logozzi, Daniela F. Angelini, Alessandro Giuliani, Davide Mizzoni, Rossella Di Raimo, Martina Maggi, Alessandro Gentilucci, Vittorio Marzio, Stefano Salciccia, Giovanna Borsellino, Luca Battistini, Alessandro Sciarra, Stefano Fais

Research output: Contribution to journalArticle

Abstract

Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.

Original languageEnglish
Article number1449
JournalCancers
Volume11
Issue number10
DOIs
Publication statusPublished - Oct 1 2019

Fingerprint

Exosomes
Prostatic Hyperplasia
Prostatic Neoplasms
Prospective Studies
Prostate-Specific Antigen
Flow Cytometry
Enzyme-Linked Immunosorbent Assay
Sensitivity and Specificity
Nanoparticles
Tissue Donors
Biopsy

Keywords

  • Benign prostatic hyperplasia (BPH)
  • ELISA
  • Exosomes
  • Nanoscale flow cytometry
  • Prostate cancer (PCa)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia : A prospective study. / Logozzi, Mariantonia; Angelini, Daniela F.; Giuliani, Alessandro; Mizzoni, Davide; Raimo, Rossella Di; Maggi, Martina; Gentilucci, Alessandro; Marzio, Vittorio; Salciccia, Stefano; Borsellino, Giovanna; Battistini, Luca; Sciarra, Alessandro; Fais, Stefano.

In: Cancers, Vol. 11, No. 10, 1449, 01.10.2019.

Research output: Contribution to journalArticle

@article{18e7f429e5ac4b7da809b07ae8e5eab4,
title = "Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia: A prospective study",
abstract = "Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100{\%} specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98{\%} to 100{\%} specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.",
keywords = "Benign prostatic hyperplasia (BPH), ELISA, Exosomes, Nanoscale flow cytometry, Prostate cancer (PCa)",
author = "Mariantonia Logozzi and Angelini, {Daniela F.} and Alessandro Giuliani and Davide Mizzoni and Raimo, {Rossella Di} and Martina Maggi and Alessandro Gentilucci and Vittorio Marzio and Stefano Salciccia and Giovanna Borsellino and Luca Battistini and Alessandro Sciarra and Stefano Fais",
year = "2019",
month = "10",
day = "1",
doi = "10.3390/cancers11101449",
language = "English",
volume = "11",
journal = "Cancers",
issn = "2072-6694",
publisher = "MDPI AG",
number = "10",

}

TY - JOUR

T1 - Increased plasmatic levels of psa-expressing exosomes distinguish prostate cancer patients from benign prostatic hyperplasia

T2 - A prospective study

AU - Logozzi, Mariantonia

AU - Angelini, Daniela F.

AU - Giuliani, Alessandro

AU - Mizzoni, Davide

AU - Raimo, Rossella Di

AU - Maggi, Martina

AU - Gentilucci, Alessandro

AU - Marzio, Vittorio

AU - Salciccia, Stefano

AU - Borsellino, Giovanna

AU - Battistini, Luca

AU - Sciarra, Alessandro

AU - Fais, Stefano

PY - 2019/10/1

Y1 - 2019/10/1

N2 - Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.

AB - Prostate Specific Antigen (PSA) fails to discriminate between benign prostatic hyperplasia (BPH) and Prostate Cancer (PCa), resulting in large numbers of unnecessary biopsies and missed cancer diagnoses. Nanovesicles called exosomes are directly detectable in patient plasma and here we explore the potential use of plasmatic exosomes expressing PSA (Exo-PSA) in distinguishing healthy individuals, BPH, and PCa. Exosomes were obtained from plasma samples of 80 PCa, 80 BPH, and 80 healthy donors (CTR). Nanoparticle Tracking Analysis (NTA), immunocapture-based ELISA (IC-ELISA), and nanoscale flow-cytometry (NSFC), were exploited to detect and characterize plasmatic exosomes. Statistical analysis showed that plasmatic exosomes expressing both CD81 and PSA were significantly higher in PCa as compared to both BPH and CTR, reaching 100% specificity and sensitivity in distinguishing PCa patients from healthy individuals. IC-ELISA, NSFC, and Exo-PSA consensus score (EXOMIX) showed 98% to 100% specificity and sensitivity for BPH-PCa discrimination. This study outperforms the conventional PSA test with a minimally invasive widely exploitable approach.

KW - Benign prostatic hyperplasia (BPH)

KW - ELISA

KW - Exosomes

KW - Nanoscale flow cytometry

KW - Prostate cancer (PCa)

UR - http://www.scopus.com/inward/record.url?scp=85073472735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073472735&partnerID=8YFLogxK

U2 - 10.3390/cancers11101449

DO - 10.3390/cancers11101449

M3 - Article

AN - SCOPUS:85073472735

VL - 11

JO - Cancers

JF - Cancers

SN - 2072-6694

IS - 10

M1 - 1449

ER -